Skip to main content
. 2021 Aug 16;13:6451–6471. doi: 10.2147/CMAR.S322179

Figure 10.

Figure 10

The associations between risk score and response to immune checkpoints ICIs therapy. (A–D) The response to anti-PD1 or anti-CTLA4 in high-risk and low-risk groups.